VHL Ligand 14

MedChemExpress

Cat. No.:	HY-150803			
CAS No.:	2010986-87-3			
Molecular Formula:	C ₂₅ H ₃₄ N ₄ O ₄ S			
Molecular Weight:	486.63			
Target:	Ligands for E3 Ligase			
Pathway:	PROTAC			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	6 months	
		-20°C	1 month	

R

SOLVENT & SOLUBILITY

In Vitro	0,	DMSO : ≥ 100 mg/mL (205.49 mM) * "≥" means soluble, but saturation unknown.						
		Solvent Mass Concentration	1 mg	5 mg	10 mg			
	Preparing Stock Solutions	1 mM	2.0549 mL	10.2747 mL	20.5495 mL			
	Stock Solutions	5 mM	0.4110 mL	2.0549 mL	4.1099 mL			
		10 mM	0.2055 mL	1.0275 mL	2.0549 mL			
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.						

BIOLOGICAL ACTIVITY					
BIOLOGICAL ACTIVITY					
Description	VHL Ligand 14 (Compound 11) is a VHL ligand for design of PROTAC estrogen receptor α (ERα) degraders, with a binding affinity IC ₅₀ of 196 nM ^[1] .				
In Vitro	VHL Ligand 14 (5-10 μM) supports the stability of PROTAC ER degrader, promotes the ER degradation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]				
	Cell Line:	MCF-7			
	Concentration:	5-10 μΜ			
	Incubation Time:	4 h			
	Result:	Inhibited degradation of ER ligand.			



ö

0 HN

REFERENCES

[1]. Hu J, et al., Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J Med Chem. 2019 Feb 14;62(3):1420-1442.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA